Slingshot members are tracking this event:

Aimmune (AIMT) Expects to Begin Open-Label Rollover Trial From PALISADE in Q4 2016 Evaluating AR101 in Treatment of Peanut Allergies: Follow-on Study named ARC004

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 08, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Open-label Rollover Trial, Arc004, Phase 3 Palisade Trial, Ar101, Peanut Allergies